[
    [
        {
            "time": "2021-11-12",
            "original_text": "君实生物火速收问询函 PD-1产品安全性遭质疑 问询",
            "features": {
                "keywords": [
                    "君实生物",
                    "PD-1",
                    "产品安全性",
                    "问询函"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "君实生物火速收问询函 PD-1产品安全性遭质疑 问询",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "沪股通净卖出17.07亿元",
            "features": {
                "keywords": [
                    "沪股通",
                    "净卖出"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沪股通净卖出17.07亿元",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "恒瑞医药治疗慢性心力衰竭药脯氨酸恒格列净片获临床试验批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "慢性心力衰竭",
                    "脯氨酸恒格列净片",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药治疗慢性心力衰竭药脯氨酸恒格列净片获临床试验批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "中国生物制药抓住黄金机遇，龙头企业纷纷落户瑞士巴塞尔大区",
            "features": {
                "keywords": [
                    "中国生物制药",
                    "黄金机遇",
                    "瑞士巴塞尔大区"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中国生物制药抓住黄金机遇，龙头企业纷纷落户瑞士巴塞尔大区",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "盛视早参：周期萌动 科技承压",
            "features": {
                "keywords": [
                    "周期萌动",
                    "科技承压"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "周期"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "盛视早参：周期萌动 科技承压",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "陆股通连续净卖出股名单",
            "features": {
                "keywords": [
                    "陆股通",
                    "净卖出"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "陆股通连续净卖出股名单",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "3款单抗拟纳入优先审评！百亿“K”药第七大新适应症来袭；默沙东、恒瑞、杨森",
            "features": {
                "keywords": [
                    "单抗",
                    "优先审评",
                    "K药",
                    "恒瑞",
                    "默沙东",
                    "杨森"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3款单抗拟纳入优先审评！百亿“K”药第七大新适应症来袭；默沙东、恒瑞、杨森",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "人民金融·创新药指数涨1.6% | 9个创新药临近上市，贝达药业重磅新药就要批了",
            "features": {
                "keywords": [
                    "创新药指数",
                    "贝达药业",
                    "新药上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨1.6% | 9个创新药临近上市，贝达药业重磅新药就要批了",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "信立泰之危：市盈率超过恒瑞医药 业绩却大跌62% 盈利能力下降",
            "features": {
                "keywords": [
                    "信立泰",
                    "市盈率",
                    "恒瑞医药",
                    "业绩下跌"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "信立泰之危：市盈率超过恒瑞医药 业绩却大跌62% 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-12",
            "original_text": "君实生物H股跌近5%领跌医药股 市场关注医保谈判结果",
            "features": {
                "keywords": [
                    "君实生物",
                    "H股",
                    "医保谈判"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "君实生物H股跌近5%领跌医药股 市场关注医保谈判结果",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]